Approved Hospital Formulary
Add Formweb to your mobile device
Approved Hospital Formulary
Search results for:
ustekinumab
ustekinumab
- Restricted Stelara --> Restricted to Outpatient Medical.
- Restricted Miscellaneous Program Formulary
- Non-formulary (Starjemza)
- Therapeutic Interchange
| Drug Name | Form | Strength | Formulary Unrestricted | Formulary Restricted | Non-Formulary | Interchange |
|---|---|---|---|---|---|---|
| Imudolsa | INJECTION, SUBCUTANEOUS | 45 mg / 0.5 mL, 90 mg / mL | ||||
| Otulfi | INJECTION, SUBCUTANEOUS | 45 mg / 0.5 mL | ||||
| Pyzchiva | INJECTION, SUBCUTANEOUS | 45 mg / 0.5 mL, 90 mg / mL | ||||
| Starjemza | INJECTION, SUBCUTANEOUS | 45 mg / 0.5 mL | ||||
| Steqeyma | INJECTION, SUBCUTANEOUS | 45 mg / 0.5 mL, 90 mg / mL | ||||
| Yesintek | INJECTION, SUBCUTANEOUS | 45 mg / 0.5 mL, 90 mg / mL | ||||
| Selarsdi | INJECTION, SUBCUTANEOUS | 90 mg / mL | ||||
| Wezlana | INJECTION, SUBCUTANEOUS | 90 mg / mL | ||||
| Stelara PFS | SOLUTION, SUBCUTANEOUS | 45 mg / 0.5 mL, 90 mg / mL |
Last updated: Jan. 30, 2026
Stelara medication guide
Stelara and the ustekinumab biosimilar products are classified as formulary restricted to the intravenous administration route by gastroenterologists in the hospital outpatient setting. The subcutaneous dosage form is classified as non-formulary and is intended for patient self-administration.
All ustekinumab biosimilars are classified as therapeutically equivalent and interchangeable for the FDA-approved indications and literature supported off-label uses. The most cost-effective agent will be used in a given patient, setting, or time period.
Reviewed: October 27, 2010, September 2025 (Biosimilars), January 2026 (Starjemza)
Ustekinumab (Stelara) Biosimilar Comparison Chart.pdf
Yesintek.pdf